Cellebrite DI Ltd (NASDAQ: CLBT) has experienced a decline in its stock price by -12.38 compared to its previous closing price of 20.12. However, the company has seen a fall of -7.61% in its stock price over the last five trading days. seekingalpha.com reported 2025-05-14 that Cellebrite DI Ltd. (NASDAQ:CLBT ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Andrew Kramer – IR Tom Hogan – Interim CEO Dana Gerner – CFO Marcus Jewell – CRO Ronnen Armon – Chief Products and Technology Officer Conference Call Participants Tomer Zilberman – Bank of America Jeff Rhee – Craig-Hallum Mike Cikos – Needham Jonathan Ho – William Blair Shaul Eyal – TD Cowen Eric Martinuzzi – Lake Street Operator Welcome to the Cellebrite First Quarter 2025 Financial Results Conference Call.
Is It Worth Investing in Cellebrite DI Ltd (NASDAQ: CLBT) Right Now?
The 36-month beta value for CLBT is also noteworthy at 1.41. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CLBT is 87.60M, and at present, short sellers hold a 1.13% of that float. The average trading volume of CLBT on May 14, 2025 was 1.44M shares.
CLBT’s Market Performance
The stock of Cellebrite DI Ltd (CLBT) has seen a -7.61% decrease in the past week, with a -7.46% drop in the past month, and a -29.26% fall in the past quarter. The volatility ratio for the week is 3.73%, and the volatility levels for the past 30 days are at 3.29% for CLBT. The simple moving average for the past 20 days is -9.00% for CLBT’s stock, with a -7.26% simple moving average for the past 200 days.
Analysts’ Opinion of CLBT
Many brokerage firms have already submitted their reports for CLBT stocks, with Needham repeating the rating for CLBT by listing it as a “Buy.” The predicted price for CLBT in the upcoming period, according to Needham is $13.50 based on the research report published on March 28, 2024 of the previous year 2024.
BofA Securities gave a rating of “Buy” to CLBT, setting the target price at $12 in the report published on February 16th of the previous year.
CLBT Trading at -7.03% from the 50-Day Moving Average
After a stumble in the market that brought CLBT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.97% of loss for the given period.
Volatility was left at 3.29%, however, over the last 30 days, the volatility rate increased by 3.73%, as shares sank -8.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.89% lower at present.
During the last 5 trading sessions, CLBT fell by -7.29%, which changed the moving average for the period of 200-days by +26.58% in comparison to the 20-day moving average, which settled at $19.37. In addition, Cellebrite DI Ltd saw -19.98% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLBT starting from LEEOR MOSHE BEN-PERETZ, who proposed sale 18,512 shares at the price of $20.36 back on Mar 25 ’25. After this action, LEEOR MOSHE BEN-PERETZ now owns shares of Cellebrite DI Ltd, valued at $376,996 using the latest closing price.
LEEOR MOSHE BEN-PERETZ, the Officer of Cellebrite DI Ltd, proposed sale 15,680 shares at $18.94 during a trade that took place back on Mar 19 ’25, which means that LEEOR MOSHE BEN-PERETZ is holding shares at $296,920 based on the most recent closing price.
Stock Fundamentals for CLBT
Current profitability levels for the company are sitting at:
- 0.14 for the present operating margin
- 0.84 for the gross margin
The net margin for Cellebrite DI Ltd stands at -0.71. The total capital return value is set at 0.14. Equity return is now at value -152.88, with -45.76 for asset returns.
Based on Cellebrite DI Ltd (CLBT), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at 12.05. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is 0.17.
Currently, EBITDA for the company is 67.51 million with net debt to EBITDA at -2.68. When we switch over and look at the enterprise to sales, we see a ratio of 10.07. The receivables turnover for the company is 4.87for trailing twelve months and the total asset turnover is 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.90.
Conclusion
In summary, Cellebrite DI Ltd (CLBT) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
